PSMA as a potential therapeutic target for T cell redirection in prostate cancer was shown in a previous phase 1 study of JNJ-63898081, a first-generation T cell engager binding to PSMA-expressing cdose-limiting toxicities (DLTs) were observedells and CD3-expressing T cells, administered by intravenous or subcutaneous (SC) dosing in 39 participants with mCRPC [5]. This evidence concerns the gene FOLH1 and prostate cancer.